化基因系统的变化导致与年龄相关的黄斑退化,并影响治疗结果
Alexander Kai Thomsen1,2, Maria Abildgaard Steffensen3, Amalie Thomsen Nielsen1,2
1Department of Ophthalmology, Zealand University Hospital, Roskilde, Denmark.
Investigative ophthalmology & visual science
|May 6, 2025
概括
化基因系统的失调与新血管与年龄相关的黄斑变性 (nAMD) 治疗反应不佳有关. 这表明,化学基因系统可能是nAMD的治疗点. 需要进一步的研究.
科学领域:
- 眼科医生 眼科 眼科
- 免疫学 免疫学 免疫学
- 遗传学 遗传学 是一个
背景情况:
- 化基因系统与与年龄相关的黄斑变性 (AMD) 有关.
- 之前的研究表明,化学因子和AMD病原体之间存在联系.
- 了解化学激素参与治疗反应对于AMD管理至关重要.
研究的目的:
- 在新血管AMD (nAMD) 和中级AMD (iAMD) 中研究化学和化学受体.
- 在nAMD中评估化基因系统与治疗反应之间的关联.
- 探索化基因系统组件与AMD风险基因型之间的关系.
主要方法:
- 包括nAMD,iAMD患者和健康对照在内的前性队列研究.
- 通过免疫试验测量血化基因度 (CCL2,CCL3,CCL4,CCL20,CXCL8,CXCL10).
- 在T细胞和单细胞上对化学因子受体表达 (CCR1,CCR2,CCR5,CCR6,CXCR2,CXCR3,CX3CR1) 的流细胞计分析.
- 对CFH和ARMS2风险多态度的相关性网络分析和基因定型.
主要成果:
- 与良好反应者相比,在nAMD初始或1年治疗反应不佳的患者显示,特定单细胞子集 (例如CD4+CXCR3+,CCR2+非经典单细胞) 的比例明显较低.
- 相关性网络表明,在部分或不良治疗反应的患者中,更复杂的化学激素系统调节.
- 几种化学激素和化学激素受体与CFH和ARMS2风险基因型显著相关.
结论:
- 经历治疗反应不佳的nAMD患者表现出化学激素系统失调.
- 化基因系统为nAMD的新疗法提供了潜在的治疗标.
- 需要进一步的研究,以充分阐明化学激素系统在nAMD治疗反应中的作用.
更多相关视频
09:24A Protocol to Evaluate and Quantify Retinal Pigmented Epithelium Pathologies in Mouse Models of Age-Related Macular Degeneration
Published on: March 10, 2023
1.4K
05:14Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
974
相关概念视频
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
868
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
868
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
376
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
376